Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

84.71 +0.66 (+0.79%)
Official Closing Price Updated: 7:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Earnings Scheduled For February 4, 2025
 
Via Benzinga
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is... 
Via Benzinga
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
 
Via Benzinga
5 Top Stocks to Buy in February 2025
All of them have great upside. 
Via The Motley Fool
A Closer Look at Merck & Co's Options Market Dynamics
 
Via Benzinga
Forecasting The Future: 12 Analyst Projections For Merck & Co
 
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:MRK.
Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics. 
Via Chartmill
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
Via The Motley Fool
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
From Merck & Co., Inc.
Via Business Wire
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
From Merck & Co., Inc.
Via Business Wire
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr. 
Via Investor's Business Daily
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
From Merck & Co., Inc.
Via Business Wire
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment. 
Via Benzinga
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing
Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality. 
Via Benzinga
Topics Lawsuit
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine. 
Via Investor's Business Daily
Topics Artificial Intelligence
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Earnings Season Scorecard And Fresh Analyst Reports For Chevron, Merck & Others
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, Merck & Co., Inc., and QUALCOMM Incorporated, as well as two micro-cap stocks CSP Inc. and AMCON... 
Via Talk Markets
Topics Stocks / Equities
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback